Equity · Healthcare
UTHR
NASDAQUnited Therapeutics (UTHR)
The line runs 475.61 USD on 25 September through 595.58 USD on 11 November, on a scale from 450 to 650. Days the market did not trade hold the previous close, flat.
- Market cap
- 25.4B USD
- P/E (TTM)
- 22.5
- Revenue, year to Dec 2025
- 3.2B USD
- EPS, diluted, year to Dec 2025
- 27.86 USD
- 52-week range
- 437 USD – 607.43 USD
- Avg volume
- 48.4K
as of Nov 11, 2026
Have United Therapeutics (UTHR) insiders bought or sold shares recently?
In the 90 days to 14 Nov 2026, United Therapeutics insiders reported 70 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Nov 2026, show no open-market purchase.
Form 4, 90 days to 14 Nov 2026, newest reported trade 11 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.6M USD |
| 10 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.6M USD |
| 09 Nov 2026 | PATUSKY CHRISTOPHERDirector | Sell | 1,210 | 702K USD |
| 09 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.5M USD |
| 06 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.4M USD |
| 05 Nov 2026 | MAHON PAUL AEVP & GENERAL COUNSEL | Sell | 8,300 | 5.0M USD |
| 05 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.5M USD |
| 04 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.7M USD |
| 03 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.7M USD |
| 02 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.7M USD |
| 30 Oct 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.7M USD |
| 29 Oct 2026 | ROTHBLATT MARTINE AChairperson & CEO | Sell | 9,500 | 5.7M USD |
| Sold | 70 open-market sales | 640,238 | $342.07M |
Showing the 12 most recent of 70 open-market trades in this window. The figures above count all of them.
70 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 10 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 09 Nov 2026 | PATUSKY CHRISTOPHERDirector | Option exercise | 1,210 | 160K USD |
| 09 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 06 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 05 Nov 2026 | MAHON PAUL AEVP & GENERAL COUNSEL | Option exercise | 8,300 | 1.2M USD |
| 05 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 04 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 03 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 02 Nov 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 30 Oct 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
| 29 Oct 2026 | ROTHBLATT MARTINE AChairperson & CEO | Option exercise | 9,500 | 1.1M USD |
Showing the 12 most recent of 70 compensation filings in this window. The figures above count all of them.
Which funds hold United Therapeutics (UTHR)?
2 of the 45 institutional funds we track reported a United Therapeutics position for the quarter ended 30 Sep 2026 — a combined 929.3M USD; the latest of those filings landed 12 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 1,675,899 | 908.2M USD | −1.9% |
| Fisher Asset Management | Held (±25%) | 38,973 | 21.1M USD | +15.2% |
Have members of Congress traded United Therapeutics (UTHR)?
The most recent congressional trade disclosed in United Therapeutics is a sale by Lisa C. McClain (house, MI), dated 31 Oct 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 31 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 21 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 22 days |
| 30 Oct 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 22 days |
What has been filed or recorded for United Therapeutics (UTHR)?
The filings we hold for United Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 55 shares | 29K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 32 shares | 18K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 5.71 USD | |
| 30 Sep 2026 | Financials | Total assets | 7.0B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 6.3B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 7.27 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 5.82 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 27.86 USD | |
| 31 Dec 2025 | Financials | Revenue | 3.2B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 1.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 27.86 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 7.16 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 6.41 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 6.63 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 24.64 USD |
What do people ask about United Therapeutics (UTHR)?
What did United Therapeutics shares close at?595.58
United Therapeutics closed at 595.58 USD on 11 Nov 2026, up 1.28% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is United Therapeutics’ market cap?25.4B
United Therapeutics is worth 25.4B USD by market value as of 11 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is United Therapeutics’ P/E ratio?22.5
United Therapeutics has a price-to-earnings ratio of 22.5, as of 11 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is United Therapeutics’ revenue?3.2B
United Therapeutics reported revenue of 3.2B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have United Therapeutics insiders bought or sold shares recently?70 sales
In the 90 days to 14 Nov 2026, United Therapeutics insiders reported 70 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Nov 2026, show no open-market purchase. A further 70 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own United Therapeutics?2 of 45
2 of the 45 funds we track reported a United Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies and Fisher Asset Management. See Funds
Have members of Congress traded United Therapeutics?3 trades
Yes. 3 trades in United Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Lisa C. McClain (House, MI) dated 31 Oct 2025, filed 21 Nov 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did United Therapeutics last report earnings?5.71
United Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 5.71 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Lisa C. McClain: Office of Congresswoman Lisa McClain, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings